DigestRedComo funciona
Red
/
Empresas
TR
No verificado

TRex Bio, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

10 Comunicados de prensa

Ver todos los comunicados de prensa
26/08/2026
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
30/06/2026
Industria
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
07/05/2026
Eventos
Industria
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
29/04/2026
Industria
Biotecnología
Farmacéutica
Salud
Medicina - Varios
TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
27/01/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
03/09/2025
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Eventos
TRexBio to Participate in Upcoming Investor Conferences in September
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
03/06/2025
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Industria
TRexBio Doses First Participant in Phase 1 Trial of TRB-061, a Novel TNFR2 Agonist for Atopic Dermatitis and Other Inflammatory Diseases
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
08/04/2025
Mercado laboral
Ciencia
Biotecnología
Sanidad
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
13/11/2024
Mercado laboral
Salud
Sanidad
Ciencia
Farmacéutica
Biotecnología
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0
26/06/2024
Mercado laboral
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Sanidad
TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases
Fuente
TRex Bio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0